Scribe Therapeutics, Inc.

SCTXReported to SECin USCIK 0001853921Filings at SEC EDGAR

No score on this page, by design. Everything here is a fact from a public U.S. register: insider filings at the SEC (Form 4), lobbying filings under the Lobbying Disclosure Act, trades reported by members of Congress under the STOCK Act, and fund holdings in 13F filings. Our scores, percentiles and signals run on the Dutch register only, because that is the only register the model has been validated on.

This page is free to read, and it stops after 5 rows. Those are the 5 most recent Form 4 lines at this company, out of 35. Reading the whole list, and the full version of each filer's page, is part of the subscription. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.

The most recent filings

Most recent filing first: every line of every Form 4 at this company that passed our review, the same lines as on the register. Reported is the day the filing reached the SEC, usually within two business days of the trade. Amounts are in U.S. dollars, as the form states them.

5 of 35
Form 4 lines at Scribe Therapeutics, Inc., most recent filing first
Filed byTypeValueReportedFiled byValueTypeSharesReported
Doudna Jennifer A—Conversion—74,088 sharesJul 29, 2026Doudna Jennifer A—Conversion · Jul 29Conversion74,088Jul 29, 2026
Doudna Jennifer A—Conversion—12,511 sharesJul 29, 2026Doudna Jennifer A—Conversion · Jul 29Conversion12,511Jul 29, 2026
AH Bio Fund II, L.P.—Conversionnothing paid4,131,344 sharesJul 29, 2026AH Bio Fund II, L.P.nothing paidConversion · Jul 29Conversion4,131,344Jul 29, 2026
AH Bio Fund II, L.P.—Conversionnothing paid12,150,003 sharesJul 29, 2026AH Bio Fund II, L.P.nothing paidConversion · Jul 29Conversion12,150,003Jul 29, 2026
AH Bio Fund II, L.P.—Open-market buy$4,999,995333,333 sharesJul 29, 2026AH Bio Fund II, L.P.$4,999,995Buy · Jul 29Open-market buy333,333Jul 29, 2026